Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04801238
Other study ID # preGallstep
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 1, 2021
Est. completion date March 1, 2024

Study information

Verified date August 2023
Source Bispebjerg Hospital
Contact Anders Kirkegaard-klitbo, MD
Phone +4520713638
Email anders.kirkegaard-Klitbo@regionh.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In Denmark, more than 7500 cholecystectomies are performed every year. Common bile duct gallstones (CBDS) are found in 3.4% to 18% of patients undergoing cholecystectomy. A two-step approach including endoscopic retrograde cholangiography (ERC) with stone extraction and papillotomy with subsequent laparoscopic cholecystectomy has become gold standard for treatment of CBDS in Denmark. However, ERC is associated with a high risk of complications and more than 50% of patients require multiple ERCs. Recent meta analyses find that a one-step approach might be superior in terms of safety, CBDS clearance rate, hospital stay, operative time, hospital cost and stone recurrence, but much more data is needed. The preGallstep trial is an investigator-initiated multicentre randomised clinical pilot trial with blinded outcome assessment investigating a novel one-step laparoscopic cholecystectomy with common bile duct exploration and stone extraction versus conventional two-step endoscopic retrograde cholangiography with stone extraction plus a subsequent laparoscopic cholecystectomy for patients with CBDS. After enrolment, the participant will be randomised to one of the two treatment approaches. Adult patients with imaging confirmed CBDS are eligible for inclusion. Potential postoperative complications will be assessed within 90 days following the procedure. The primary outcome is the proportion of serious adverse events (corresponding to a Clavien-Dindo score II or above) requiring re-intervention within 90 days of the initial procedure. This outcome will be used for a future sample size calculation. The sample size estimate, the inclusion rate and the estimated length of subsequent trial will be used to determine the feasibility of a large pragmatic and confirmatory trial. We hypothesize that the one-step approach will significantly reduce the risk of complications and number of treatments needed thereby making a difference to hundreds of people in Denmark each year.


Description:

Purpose The preGallstep pilot trial is a pilot randomised clinical trial investigating two different surgical methods in patients with common bile duct stones: one-step laparoscopic cholecystectomy with common bile duct exploration (experimental intervention) versus two-step endoscopic retrograde cholangiography with stone extraction plus subsequent laparoscopic cholecystectomy (control intervention) for the removal of common bile duct stones. The investigators alternative hypothesis is that both patient safety, assessed by serious adverse events, as well as the number of procedures needed to obtain stone clearance are better in the one-step approach than in the control approach. However, based on updated systematic review of previously conducted randomised clinical trials (RCTs) the investigators are not able to say which procedure is preferable. Further analysis of these previous RTCs show they are very far from obtaining a confirmatory sample size, thus illustrating the need for larger multicenter trials. Prior to conducting a large pragmatic and confirmatory trial, the investigators propose this multicenter preGallstep pilot trial. The purpose of preGallstep is to assess the proportion of participants in the control group with complications in order to conduct more precise sample size estimation for a future pragmatic randomised clinical trial. Furthermore, the investigators want to assess the feasibility of implementing randomisation between different surgical techniques in a daily complex clinical setting. Background In the Nordic countries, 80 to 200 surgical removals of the gallbladder (cholecystectomies) per 100000 inhabitants are performed annually making it one of the most common surgical procedures. In Denmark, over 7500 cholecystectomies are performed every year. Cholecystectomy is most often performed due to symptomatic gallstones in the gallbladder. However, common bile duct gallstones (CBDS) are found in 3.4% to 18% of patients undergoing cholecystectomy, with highest proportions during acute surgery. However, the most efficient and safest procedure to remove CBDS has yet to be identified. A two-step approach including endoscopic retrograde cholangiography (ERC) with stone extraction and papillotomy with subsequent laparoscopic cholecystectomy has become the gold standard treatment for CBDS in Denmark. However, as the gallbladder is left in situ following successful clearance of CBDS there are high risks of symptom recurrence and gallstone complications. ERC is an advanced endoscopic procedure and multiple ERCs are required in as much as 59% of patients. Temporary stents are placed in patients with failed stone clearance during ERC. This delays stone extraction and requires repeat-ERC. Acute pancreatitis is a feared complication following ERC and is reported to occur in 4% of patients (range 2.6% to 18%). Acute pancreatitis causes high mortality and morbidity and is associated with low long-term quality of life. Other long-term complications of ERC papillotomy include recurrent bile duct stones, cholangitis, stenosis, and an unknown risk of malignant transformation. The most comprehensive study on gallstone disease included 34,200 unselected patients undergoing laparoscopic cholecystectomy and reported CBDS in 11.6% of which 16% were left untreated. In these 16%, one out of four patients experienced unfavourable outcomes such as complicated gallstone disease (pancreatitis, cholangitis, jaundice) or the need of ERC within 90 days. All other treatment strategies to remove CBDS caused lower risk of adverse events when compared to leaving CBDS untreated. The treatment of CBDS is, therefore, recommended to include both clearance of CBDS and a cholecystectomy. This one-step approach including laparoscopic common bile duct exploration with gallstoneclearance (LCBDE) plus laparoscopic cholecystectomy is an emerging minimal-invasive approach for CBDS. The one-step LCBDE plus laparoscopic cholecystectomy approach seems to cause less postoperative pancreatitis although no significant associations have been published yet. A Cochrane review of five RCTs of the one-step versus the two-step approach with ERC first including 621 patients concluded that the two approaches were comparable regarding stone clearance, morbidity, and mortality. Newer RCTs have shown comparable stone clearance proportions and comparable occurrence of short-term postoperative complications and mortality between the two approaches. The most recently published meta-analyses find that LCBDE versus ERC is superior in terms of safety (perioperative complications, conversion rate to other procedure), CBDS clearance rate, hospital stay, operative time, in hospital costs, and stones recurrence. Trial Sequential Analysis of the two approaches has been performed but due to the small sample sizes available, they were unable to make final conclusions on patient safety or CBDS removal efficiency. In order to explore what sample size was needed to make a final conclusion on patient safety, Trial Sequential Analysis including all known RCTs has been performed. The outcome of interest was adverse events defined by short-term postoperative complications as defined by the single studies. Intention-to-treat data were extracted where possible, however, some studies excluded randomised patients without CBDS at intraoperative cholangiography or patients that did not complete the protocolled treatments. Most trials randomised patients with only a clinical suspicion of CBDS and only few RCTs randomised patients with CBDS proven by MRCP or EUL. Through meta-analysis, the total proportion of adverse events was found to be 16% (102/649) in the two-step approach. Based on Trial Sequential Analyses, with a relative risk reduction 20%, α at 0.05, β at 0.10, a diversity of 0%, and when a two-sided test was used, the total sample size required was 5060 participants for adverse events. Previous trials already included 1302 participants and the trial sequential monitoring boundaries for superiority, inferiority, or futility have not been reached. The literature has, thereby, not yet identified the safest procedure or which treatment the patients prefer to remove CBDS. More research on patient safety, stone clearance, and patient-centred outcomes is needed. Methods Trial design The preGallstep pilot is an investigator-initiated multicentre randomised parallel group, clinical, pilot trial with blinded outcome assessment at 90 days. Randomisation Participants will be randomised at the allocation ratio 1:1. Web-based randomisation will be handled centrally at the Copenhagen Trial Unit (CTU) using a concealed computer-generated allocation sequence with a varying block size concealed from investigators. The allocation sequence will be stratified for trial site. A trial nurse will enroll and allocate participants. Participant timeline Both acute and non-acute patients may enter. The physician in charge will offer enrolment to eligible patients. After enrolment, the participant will be randomised to one of the two treatment approaches. Baseline data including quality of life survey will be established by the trial nurse. The patient will receive the trial intervention or control intervention no later than one week after randomisation. Follow-up for immediate complications within first 24 postoperative hours will be performed by the trial nurse (follow-up day 1). Blood samples including amylase will be drawn following the procedure. If no immediate complications occur, the patients will be discharged within 24 hours following the procedure. A 90-day clinical follow-up will be performed to assess outcomes. Registration of lost to follow-up and reasons will also be assessed here. Blinding Blinding of participants and surgeons is not possible. Most of the outcomes are dependent on physician assessment. To have blinded outcome assessment, the trial nurse who has not been part of the surgical team and who is blinded to treatment allocation will perform the follow-up visits. Outcome will be assessed by a blinded outcome committee of three experts not associated with the trial or the participating departments. Statistical plan and data analysis As this is a pilot trial, a formal sample size calculation is not necessary. A sample size of 150 participants is deemed feasible to include and randomised within 18 months, and it should be sufficient to base a formal size calculation on for the planning of a large pragmatic trial. Statistical analysis will be performed according to the intention-to-treat principle. All patient included in the trial have CBDS according to the inclusion criteria and according to the best diagnostic modalities used in the clinic today (see above) and, therefore, the intention-to-treat principle can be used without any post-randomisation exclusions as done in some previous studies. Thereby, all patients with spontaneously passed stones at intra-operative cholangiography, lost-to follow up at 90 days, or patients not undergoing the full two-step procedures will be included in the statistical analyses. Analyses of the primary outcome will be performed for differences between intervention and control group after 90 days of follow-up. Dichotomous outcomes will be analysed using logistic regression. Continuous outcomes will be analysed using linear regression or van Eltern test. Analyses will be adjusted for the stratification variable. Odds ratios or mean differences will be reported with 95% confidence intervals and P-values. As this is a pilot trial, any significant result can be due to random errors and lack of power. It is therefore purely hypothesis generating. Publications The investigators plan to publish a design article and an article describing the results of the preGallstep pilot trial. Furthermore, the results will be added to an updated meta-analysis. Authorship will be determined by the guidelines by the International Committee for Medical Journal Editors. Members of the trial steering committee as well as the principle investigator from each trial site will be invited as coauthors. Collaborations The preGallstep trial is in collaboration between five major surgical departments in Denmark. Investigators of each department have reached expert level of LC+LCBDE and have given consent of participation in the trial. Protocol development, randomisation, data management, and surveillance of the trial are in collaboration with the Copenhagen Trial Unit (CTU). CTU is a non-specialty oriented clinical intervention research unit consisting of experienced trialists, clinicians, epidemiologists, statisticians, information-technology engineers, and information specialists. Significance of the project There has not been a significant improvement to the treatment of bile stone disease since the introduction of laparoscopic surgery and ERC more than twenty years ago. Each year more than 750 new patients are diagnosed with CBDS in Denmark alone. ERC combined with LC is the treatment of choice but is affected by a high rate of severe complications and the risk of extended course of treatment. The investigators propose a new method of treatment that might significantly reduce risk of complications, number of treatments needed, cost to society and improve patient satisfaction and make a difference to hundreds of people in Denmark alone each year. Since this is a poorly researched area and large RCTs is needed it is important to make the necessary preparations by conducting a large pilot RCT


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date March 1, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Common bile duct stones identified by magnetic resonance cholangiopancreatography (MRCP). - Age 18 years or older. - Both interventions must be possible to perform within a clinically reasonable timeframe, as assessed by the investigator. - Informed consent. Exclusion Criteria: Patients with acute cholangitis corresponding to a grade III (elevated serum bilirubin, fever, and/or elevated white blood cell count and signs of severe organ failure) according to Tokyo guidelines 2018 including severe organ failure. - Common bile duct cysts shown by magnetic resonance cholangiopancreatography (MRCP), ultrasonography, computer tomography (CT), or cholangiography. - Pancreatic/biliary/hepatic malignancies. - Prior cholecystectomy or sphincterotomy. - Chronic pancreatitis. - If assessed by investigator that laparoscopic cholecystectomy is not possible, e.g. due to prior surgery or patient condition. - Gastric bypass. - Pregnancy confirmed by elevated choriogonadotropin (hCG) in women below 60 years. - No informed consent.

Study Design


Intervention

Procedure:
LCBDE + LC
Experimental group: Laparoscopic common bile duct exploration (LCBDE) + laparoscopic cholecystectomy (LC) is performed under full anaesthesia. Once the dissection has exposed the cystic a clip or ligature is placed peripherally on the cystic duct. Through an incision in the duct central to the clip or ligature a cholangiogram catheter is introduced into the cystic duct and the cholangiogram is completed. After identification of the bile duct stones and anatomy, a cholangioscope is introduced through the duct incision into common bile duct. The stones are identified visually and removed by Dormia basket. If the stones are very large, they may be partitioned mechanically or by electrohydraulic lithotripsy. In the presence of CBDS wedged in the papilla these stones will be removed and a secondary cholangiogram will be performed. Subsequently, the cholangioscope is taken out. Then the cystic duct is divided and the gallbladder is dissected out from the liver by hook cautery and removed.
ERC + LC
Control intervention: (First step) Endoscopic retrograde cholangiography (ERC) is routinely performed in sedation but or in full anaesthesia. ERC is performed with the patient in the supine position. The endoscope is passed down to the second part of the duodenum where the papilla is identified. Cannulation of the papilla and the common bile duct is performed with a papillotome and a guidewire. A cholangiography will confirm the presence, location and size of the CBDS and aims in further choice of extraction method. Stones can be extracted by papillotomy and by either balloon or by a basket. Additional balloon dilation of the papilla, or lithotripsy may be required. If stone extraction is incomplete or if the conditions are unclear a temporary common bile duct stent is placed which has to be removed with additional ERC after 1-2 months (Second step) laparoscopic cholecystectomy is performed after 2-14 days

Locations

Country Name City State
Denmark Digestive disease center, Bispebjerg Hospital Copenhagen NV Not In US/Canada

Sponsors (2)

Lead Sponsor Collaborator
Lars Tue Sorensen Copenhagen Trial Unit, Center for Clinical Intervention Research

Country where clinical trial is conducted

Denmark, 

References & Publications (40)

ASGE Standards of Practice Committee; Buxbaum JL, Abbas Fehmi SM, Sultan S, Fishman DS, Qumseya BJ, Cortessis VK, Schilperoort H, Kysh L, Matsuoka L, Yachimski P, Agrawal D, Gurudu SR, Jamil LH, Jue TL, Khashab MA, Law JK, Lee JK, Naveed M, Sawhney MS, Thosani N, Yang J, Wani SB. ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasis. Gastrointest Endosc. 2019 Jun;89(6):1075-1105.e15. doi: 10.1016/j.gie.2018.10.001. Epub 2019 Apr 9. — View Citation

Balandraud P, Biance N, Peycru T, Tardat E, Bonnet PM, Cazeres C, Hardwigsen J. Fortuitous discovery of common bile duct stones: results of a conservative strategy. Gastroenterol Clin Biol. 2008 Apr;32(4):408-12. doi: 10.1016/j.gcb.2008.02.023. Epub 2008 Apr 9. — View Citation

Bansal VK, Misra MC, Garg P, Prabhu M. A prospective randomized trial comparing two-stage versus single-stage management of patients with gallstone disease and common bile duct stones. Surg Endosc. 2010 Aug;24(8):1986-9. doi: 10.1007/s00464-010-0891-7. Ep — View Citation

Bansal VK, Misra MC, Rajan K, Kilambi R, Kumar S, Krishna A, Kumar A, Pandav CS, Subramaniam R, Arora MK, Garg PK. Single-stage laparoscopic common bile duct exploration and cholecystectomy versus two-stage endoscopic stone extraction followed by laparosc — View Citation

Barreras Gonzalez JE, Torres Pena R, Ruiz Torres J, Martinez Alfonso MA, Brizuela Quintanilla R, Morera Perez M. Endoscopic versus laparoscopic treatment for choledocholithiasis: a prospective randomized controlled trial. Endosc Int Open. 2016 Nov;4(11):E — View Citation

Boerma D, Rauws EA, Keulemans YC, Janssen IM, Bolwerk CJ, Timmer R, Boerma EJ, Obertop H, Huibregtse K, Gouma DJ. Wait-and-see policy or laparoscopic cholecystectomy after endoscopic sphincterotomy for bile-duct stones: a randomised trial. Lancet. 2002 Sep 7;360(9335):761-5. doi: 10.1016/S0140-6736(02)09896-3. — View Citation

Castoldi L, De Rai P, Zerbi A, Frulloni L, Uomo G, Gabbrielli A, Bassi C, Pezzilli R; ProInf-AISP (Progetto Informatizzato Pancreatite Acuta, Associazione Italiana per lo Studio del Pancreas) Study Group. Long term outcome of acute pancreatitis in Italy: results of a multicentre study. Dig Liver Dis. 2013 Oct;45(10):827-32. doi: 10.1016/j.dld.2013.03.012. Epub 2013 Jul 3. — View Citation

Coelho-Prabhu N, Shah ND, Van Houten H, Kamath PS, Baron TH. Endoscopic retrograde cholangiopancreatography: utilisation and outcomes in a 10-year population-based cohort. BMJ Open. 2013 May 31;3(5):e002689. doi: 10.1136/bmjopen-2013-002689. — View Citation

Collins C, Maguire D, Ireland A, Fitzgerald E, O'Sullivan GC. A prospective study of common bile duct calculi in patients undergoing laparoscopic cholecystectomy: natural history of choledocholithiasis revisited. Ann Surg. 2004 Jan;239(1):28-33. doi: 10.1097/01.sla.0000103069.00170.9c. — View Citation

Cuschieri A, Lezoche E, Morino M, Croce E, Lacy A, Toouli J, Faggioni A, Ribeiro VM, Jakimowicz J, Visa J, Hanna GB. E.A.E.S. multicenter prospective randomized trial comparing two-stage vs single-stage management of patients with gallstone disease and du — View Citation

Das SL, Singh PP, Phillips AR, Murphy R, Windsor JA, Petrov MS. Newly diagnosed diabetes mellitus after acute pancreatitis: a systematic review and meta-analysis. Gut. 2014 May;63(5):818-31. doi: 10.1136/gutjnl-2013-305062. Epub 2013 Aug 8. — View Citation

Dasari BV, Tan CJ, Gurusamy KS, Martin DJ, Kirk G, McKie L, Diamond T, Taylor MA. Surgical versus endoscopic treatment of bile duct stones. Cochrane Database Syst Rev. 2013 Dec 12;2013(12):CD003327. doi: 10.1002/14651858.CD003327.pub4. — View Citation

Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13. doi: 10.1097/01.sla.0000133083.54934.ae. — View Citation

Ding G, Cai W, Qin M. Single-stage vs. two-stage management for concomitant gallstones and common bile duct stones: a prospective randomized trial with long-term follow-up. J Gastrointest Surg. 2014 May;18(5):947-51. doi: 10.1007/s11605-014-2467-7. Epub 2 — View Citation

Ding X, Zhang F, Wang Y. Risk factors for post-ERCP pancreatitis: A systematic review and meta-analysis. Surgeon. 2015 Aug;13(4):218-29. doi: 10.1016/j.surge.2014.11.005. Epub 2014 Dec 24. — View Citation

Frimberger E. Long-term sequelae of endoscopic papillotomy. Endoscopy. 1998 Nov;30(9):A221-7. doi: 10.1055/s-2007-1001444. No abstract available. — View Citation

Frossard JL, Hadengue A, Amouyal G, Choury A, Marty O, Giostra E, Sivignon F, Sosa L, Amouyal P. Choledocholithiasis: a prospective study of spontaneous common bile duct stone migration. Gastrointest Endosc. 2000 Feb;51(2):175-9. doi: 10.1016/s0016-5107(00)70414-7. — View Citation

Hakamada K, Sasaki M, Endoh M, Itoh T, Morita T, Konn M. Late development of bile duct cancer after sphincteroplasty: a ten- to twenty-two-year follow-up study. Surgery. 1997 May;121(5):488-92. doi: 10.1016/s0039-6060(97)90101-x. — View Citation

Hammarstrom LE, Holmin T, Stridbeck H, Ihse I. Long-term follow-up of a prospective randomized study of endoscopic versus surgical treatment of bile duct calculi in patients with gallbladder in situ. Br J Surg. 1995 Nov;82(11):1516-21. doi: 10.1002/bjs.1800821121. — View Citation

Horiuchi A, Nakayama Y, Kajiyama M, Kato N, Kamijima T, Graham DY, Tanaka N. Biliary stenting in the management of large or multiple common bile duct stones. Gastrointest Endosc. 2010 Jun;71(7):1200-1203.e2. doi: 10.1016/j.gie.2009.12.055. Epub 2010 Apr 18. — View Citation

Jarvinen TL, Sihvonen R, Bhandari M, Sprague S, Malmivaara A, Paavola M, Schunemann HJ, Guyatt GH. Blinded interpretation of study results can feasibly and effectively diminish interpretation bias. J Clin Epidemiol. 2014 Jul;67(7):769-72. doi: 10.1016/j.jclinepi.2013.11.011. Epub 2014 Feb 20. — View Citation

Koc B, Karahan S, Adas G, Tutal F, Guven H, Ozsoy A. Comparison of laparoscopic common bile duct exploration and endoscopic retrograde cholangiopancreatography plus laparoscopic cholecystectomy for choledocholithiasis: a prospective randomized study. Am J — View Citation

Lv F, Zhang S, Ji M, Wang Y, Li P, Han W. Single-stage management with combined tri-endoscopic approach for concomitant cholecystolithiasis and choledocholithiasis. Surg Endosc. 2016 Dec;30(12):5615-5620. doi: 10.1007/s00464-016-4918-6. Epub 2016 Apr 28. — View Citation

Miura F, Okamoto K, Takada T, Strasberg SM, Asbun HJ, Pitt HA, Gomi H, Solomkin JS, Schlossberg D, Han HS, Kim MH, Hwang TL, Chen MF, Huang WS, Kiriyama S, Itoi T, Garden OJ, Liau KH, Horiguchi A, Liu KH, Su CH, Gouma DJ, Belli G, Dervenis C, Jagannath P, Chan ACW, Lau WY, Endo I, Suzuki K, Yoon YS, de Santibanes E, Gimenez ME, Jonas E, Singh H, Honda G, Asai K, Mori Y, Wada K, Higuchi R, Watanabe M, Rikiyama T, Sata N, Kano N, Umezawa A, Mukai S, Tokumura H, Hata J, Kozaka K, Iwashita Y, Hibi T, Yokoe M, Kimura T, Kitano S, Inomata M, Hirata K, Sumiyama Y, Inui K, Yamamoto M. Tokyo Guidelines 2018: initial management of acute biliary infection and flowchart for acute cholangitis. J Hepatobiliary Pancreat Sci. 2018 Jan;25(1):31-40. doi: 10.1002/jhbp.509. Epub 2018 Jan 8. — View Citation

Moller M, Gustafsson U, Rasmussen F, Persson G, Thorell A. Natural course vs interventions to clear common bile duct stones: data from the Swedish Registry for Gallstone Surgery and Endoscopic Retrograde Cholangiopancreatography (GallRiks). JAMA Surg. 2014 Oct;149(10):1008-13. doi: 10.1001/jamasurg.2014.249. — View Citation

Noble H, Tranter S, Chesworth T, Norton S, Thompson M. A randomized, clinical trial to compare endoscopic sphincterotomy and subsequent laparoscopic cholecystectomy with primary laparoscopic bile duct exploration during cholecystectomy in higher risk pati — View Citation

Pan L, Chen M, Ji L, Zheng L, Yan P, Fang J, Zhang B, Cai X. The Safety and Efficacy of Laparoscopic Common Bile Duct Exploration Combined with Cholecystectomy for the Management of Cholecysto-choledocholithiasis: An Up-to-date Meta-analysis. Ann Surg. 20 — View Citation

Pendharkar SA, Salt K, Plank LD, Windsor JA, Petrov MS. Quality of life after acute pancreatitis: a systematic review and meta-analysis. Pancreas. 2014 Nov;43(8):1194-200. doi: 10.1097/MPA.0000000000000189. — View Citation

Petrov MS, Shanbhag S, Chakraborty M, Phillips AR, Windsor JA. Organ failure and infection of pancreatic necrosis as determinants of mortality in patients with acute pancreatitis. Gastroenterology. 2010 Sep;139(3):813-20. doi: 10.1053/j.gastro.2010.06.010. Epub 2010 Jun 9. — View Citation

Ricci C, Pagano N, Taffurelli G, Pacilio CA, Migliori M, Bazzoli F, Casadei R, Minni F. Comparison of Efficacy and Safety of 4 Combinations of Laparoscopic and Intraoperative Techniques for Management of Gallstone Disease With Biliary Duct Calculi: A Syst — View Citation

Rogers SJ, Cello JP, Horn JK, Siperstein AE, Schecter WP, Campbell AR, Mackersie RC, Rodas A, Kreuwel HT, Harris HW. Prospective randomized trial of LC+LCBDE vs ERCP/S+LC for common bile duct stone disease. Arch Surg. 2010 Jan;145(1):28-33. doi: 10.1001/a — View Citation

Ryberg AA, Fitzgibbons RJ Jr, Tseng A, Maffi TR, Burr LJ, Doris PE. Abnormal cholangiograms during laparoscopic cholecystectomy. Is treatment always necessary? Surg Endosc. 1997 May;11(5):456-9. doi: 10.1007/s004649900389. — View Citation

Sarli L, Pietra N, Franze A, Colla G, Costi R, Gobbi S, Trivelli M. Routine intravenous cholangiography, selective ERCP, and endoscopic treatment of bile duct stones before laparoscopic cholecystectomy. Gastrointest Endosc. 1999 Aug;50(2):200-8. doi: 10.1016/s0016-5107(99)70225-7. — View Citation

Sgourakis G, Karaliotas K. Laparoscopic common bile duct exploration and cholecystectomy versus endoscopic stone extraction and laparoscopic cholecystectomy for choledocholithiasis. A prospective randomized study. Minerva Chir. 2002 Aug;57(4):467-74. — View Citation

Singh AN, Kilambi R. Single-stage laparoscopic common bile duct exploration and cholecystectomy versus two-stage endoscopic stone extraction followed by laparoscopic cholecystectomy for patients with gallbladder stones with common bile duct stones: system — View Citation

Tanaka M, Takahata S, Konomi H, Matsunaga H, Yokohata K, Takeda T, Utsunomiya N, Ikeda S. Long-term consequence of endoscopic sphincterotomy for bile duct stones. Gastrointest Endosc. 1998 Nov;48(5):465-9. doi: 10.1016/s0016-5107(98)70086-0. — View Citation

Targarona EM, Ayuso RM, Bordas JM, Ros E, Pros I, Martinez J, Teres J, Trias M. Randomised trial of endoscopic sphincterotomy with gallbladder left in situ versus open surgery for common bileduct calculi in high-risk patients. Lancet. 1996 Apr 6;347(9006):926-9. doi: 10.1016/s0140-6736(96)91413-0. — View Citation

Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, Gluud LL, Als-Nielsen B, Gluud C. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol. 2009 Feb;38(1):276-86. doi: 10.1093/ije/dyn179. Epub 2008 Sep 29. — View Citation

Wetterslev J, Jakobsen JC, Gluud C. Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Med Res Methodol. 2017 Mar 6;17(1):39. doi: 10.1186/s12874-017-0315-7. — View Citation

Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med Res Methodol. 2009 Dec 30;9:86. doi: 10.1186/1471-2288-9-86. — View Citation

* Note: There are 40 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Other Quality of Life survey QoL score (SF-36) at baseline and after 90 days follow-up 90 days
Primary Postoperative complications Proportion of participants with postoperative complications corresponding to a Clavien-Dindo score of 2-5 90 days
Secondary Stone clearance failure Rate of participants with incomplete stone clearance perioperatively
Secondary Number of procedures Total number of procedures for each participant during 90 days follow-up 90 days after initial procedure
Secondary Lenght of hospital stay Total length of hospital stay for each participant 90 days
Secondary Stone size Size of biggest common bile duct stone (mm) Perioperatively
Secondary Number of stones Number of common bile duct stones perioperatively
Secondary Stone extraction pathway Is LCBDE transcystic or transcholedocal? perioperatively
Secondary Stone extraction method Equipment used for stone extraction perioperatively
Secondary Cholangiography Stones on perioperative cholangiography (yes/no) perioperatively
Secondary Procedure time Total time spend on all procedures (minutes) From start of initial procedure until 90 days follow-up
Secondary Conversion to open surgery Number of procedures converted to open surgery From start of initial procedure until 90 days follow-up
See also
  Status Clinical Trial Phase
Recruiting NCT03609944 - SpHincterotomy for Acute Recurrent Pancreatitis N/A
Not yet recruiting NCT04652271 - International Pancreatic Surgery Outcomes Study - PancreasGroup.Org
Completed NCT01441492 - Pancreas Resection With and Without Drains N/A
Recruiting NCT02196935 - Los Angeles Prospective GI Biliary and EUS Series
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Completed NCT01545167 - The North American Pancreatitis Study N/A
Completed NCT04168801 - Early Oral Refeeding in Mild Acute Pancreatitis N/A
Recruiting NCT03334708 - A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
Completed NCT01824186 - Trial Comparing Pain in Single-incision Laparoscopic Cholecystectomy Versus Conventional Laparoscopic Cholecystectomy N/A
Terminated NCT00428025 - Diclofenac for the Prevention of Post-ERCP Pancreatitis in Higher Risk Patients Phase 4
Completed NCT00639314 - Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy N/A
Recruiting NCT00160836 - Biliary Tissue Sampling Using a Cytology Brush or the GIUM Catheter Phase 1
Completed NCT00121901 - Does Glyceryl Nitrate Prevent Post-Endoscopic Retrograde Cholangiopancreaticography (ERCP) Pancreatitis? Phase 3
Completed NCT00999232 - Assess the Effect of Erythromycin on the Rate of Success in Placement of a Self-propelled Feeding Tube Phase 4
Terminated NCT00419549 - Efficacy Study of Glyceryl-Trinitrate Patch and Parecoxib (Valdecoxib) for the Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography (ERCP) Phase 2/Phase 3
Active, not recruiting NCT05095831 - EUS Shear Wave for Solid Pancreatic Lesions.
Completed NCT03601325 - Acute Pancreatitis: Study of Possible Etiologies and Risk Factors Affecting Outcome
Withdrawn NCT02465138 - A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis Phase 4
Not yet recruiting NCT06133023 - WONDER-02 Trial: Plastic Stent vs. Lumen-apposing Metal Stent for Pancreatic Pseudocysts N/A
Recruiting NCT02971475 - ESWL Versus ESWL and Endoscopic Treatment N/A